<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00360555</url>
  </required_header>
  <id_info>
    <org_study_id>511.75</org_study_id>
    <nct_id>NCT00360555</nct_id>
  </id_info>
  <brief_title>Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder</brief_title>
  <official_title>Best Tolerability: 50mg Twice Daily Versus 100 mg in the Evening Versus 25 mg Twice Daily Versus Placebo in Younger Women in North America</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sprout Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sprout Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed to assess the safety and efficacy of flibanserin in the treatment of
      premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard
      diagnostic criteria.

      Efficacy for flibanserin will be assessed vs. a parallel placebo group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Frequency of Satisfying Sexual Events (SSE) as Recorded in the eDiary.</measure>
    <time_frame>baseline to 28 weeks</time_frame>
    <description>For endpoints collected on the eDiary, responses are accumulated on a monthly basis using the following algorithms.
For satisfying sexual events:
Total monthly events = 28 x (sum of the number of events) / (sum of number of days entered)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in the Monthly Sum of Responses Recorded in the eDiary to the Daily Desire Question.</measure>
    <time_frame>baseline to 24 weeks</time_frame>
    <description>Change from baseline in the electronic diary (eDiary) Sexual Desire Monthly Total Score standardized to a 28-day period (score range 0-84). Change from baseline is calculated as the difference between the four week baseline period and Week 21 to Week 24. Patients were asked to record information daily in the eDiary throughout the trial. Every time the eDiary was completed, a desire question was asked. If a patient did not complete the diary on a given day, the patient was not asked to enter desire information for more than a 24-hour retrospective period. The desire item read &quot;Indicate your most intense level of sexual desire in the last 24 hours / since your last visit.&quot; Potential responses included &quot;no,&quot; &quot;low,&quot; &quot;moderate,&quot; or &quot;strong&quot; and was scored 0-3, with 0 indicating no desire and 3 indicating the highest level of desire:
0 = No desire
= Low desire
= Moderate desire
= Strong desire</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1584</enrollment>
  <condition>Sexual Dysfunctions, Psychological</condition>
  <arm_group>
    <arm_group_label>flibanserin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>flibanserin 25 mg b.i.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>flibanserin 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>flibanserin 50mg qhs/b.i.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>flibanserin 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>flibanserin 50mg b.i.d./100mg qhs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flibanserin</intervention_name>
    <description>flibanserin 25 mg b.i.d</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flibanserin 50mg</intervention_name>
    <description>flibanserin 50mg qhs/b.i.d.</description>
    <arm_group_label>flibanserin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flibanserin 100mg</intervention_name>
    <description>flibanserin 50 mg b.i.d/100mg qhs</description>
    <arm_group_label>flibanserin 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo comparator</description>
    <arm_group_label>flibanserin 100mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women who are 18 years of age and older.

          2. Premenopausal women having regular menstrual periods who have HSDD (decreased sexual
             desire), generalized acquired type, according to DSM IV-TR criteria.

          3. Patient must meet minimum cut-off scores on questionnaires relating to sexual
             functioning and sexual distress.

          4. Patients must be willing to try to have sexual activity (e.g., any act involving
             direct genital stimulation) at least once monthly.

          5. Patients must be willing and able to use an electronic diary on a daily basis (e.g.,
             have access to a working land line telephone for daily data transmissions).

          6. At the Baseline Visit, patients must have complied with eDiary use adequately.

          7. Patients must be in a stable, monogamous, heterosexual relationship that is secure and
             communicative, for at least 1 year prior to the Screen Visit. The partner is expected
             to be physically present at least 50% of each month.

          8. Patients must have used a medically acceptable method of contraception for at least 3
             months before the Baseline Visit (Visit 2) and continue to use that medically
             acceptable method of contraception during the trial.

          9. In the investigators opinion, patients must be reliable, honest, compliant, and agree
             to co-operate with all trial evaluations as well as to be able to perform them.

         10. Patients must be able and willing to give meaningful, written informed consent prior
             to participation in the trial, in accordance with regulatory requirements. Patients
             must have sufficient understanding to communicate effectively with the investigator,
             and be willing to discuss their sexual functioning with the investigative staff.

         11. Patients must have a clinically acceptable Pap smear as read by a cytology facility
             (no evidence of malignancy or squamous intraepithelial lesions) within 6 months before
             the Screen Visit.

         12. A score of 15 or higher on the FSDS-R at the screen Visit.

        Exclusion Criteria:

          1. Patients who have taken any medication noted in the protocols List of Prohibited
             Medications within 30 days before screening.

          2. Patients whose sexual function was affected (enhanced or worsened) in the
             investigators opinion by any medication within 30 days before the Screen Visit and
             anytime prior to the Baseline Visit.

          3. Patients with a history of drug dependence or abuse within the past one year.

          4. Patients with a history of multiple severe reactions (i.e., allergic or
             oversensitivity to usual doses) to drugs that affect the brain.

          5. Patients with a history of participation in a trial of another investigational
             medication within one month prior to the Screen Visit, or participation in any
             previous clinical trial of flibanserin.

          6. Patients who meet accepted diagnostic criteria for sexual disorders that would
             interfere with improvement in HSDD (sexual aversion, substance-induced sexual
             problems, urge to live as a man, etc.

          7. Patients who indicate that their sexual partner has inadequately treated sexual
             problems that could interfere with the patients response to treatment.

          8. Patients who have entered the menopausal transition or menopause or have had a
             hysterectomy.

          9. Patients with findings at the Screen Visit of infection, inflammation, undue
             tenderness, or shrinkage (atrophy) of the female organs.

         10. Patients who are breast feeding or have breastfed within the last 6 months prior to
             the Baseline Visit.

         11. Patients who are pregnant or have been pregnant within the last 6 months prior to the
             Baseline Visit.

         12. Patients with a history of Major Depressive Disorder within 6 months prior the Screen
             Visit, a score indicating depression on a depression scale, a history of suicide
             attempt, or current suicidal ideation evident at the Screen or Baseline Visit.

         13. Patients with a history of any other psychiatric disorders that could impact sexual
             function, risks patients safety, or may impact compliance.

         14. Patients who have started psychotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>511.75.01015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fair Oaks</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sacremento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01065 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01066 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Meyers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01073 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palm Bay</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bingham Farms</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chaska</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01069 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Medfod</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01067 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01070 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01064 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01068 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.01036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Middleton</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.02008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.02002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.02004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Woodstock</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.02005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mount Pearl</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.02010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.02011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.02001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.02007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.02009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.02013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trois-Rivi√®res</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.02003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.02012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.75.02014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2006</study_first_submitted>
  <study_first_submitted_qc>August 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2006</study_first_posted>
  <results_first_submitted>March 27, 2014</results_first_submitted>
  <results_first_submitted_qc>June 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2016</results_first_posted>
  <last_update_submitted>June 6, 2016</last_update_submitted>
  <last_update_submitted_qc>June 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Flibanserin 25 mg b.i.d</title>
          <description>flibanserin: 25 mg twice daily</description>
        </group>
        <group group_id="P2">
          <title>Flibanserin 50mg Qhs/b.i.d</title>
          <description>flibanserin: 50 mg once at bedtime/twice daily</description>
        </group>
        <group group_id="P3">
          <title>Flibanserin 50mg b.i.d./100mg Qhs</title>
          <description>flibanserin: 50 mg twice daily/100 once at bedtime</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>flibanserin: placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="396"/>
                <participants group_id="P2" count="393"/>
                <participants group_id="P3" count="396"/>
                <participants group_id="P4" count="399"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="274"/>
                <participants group_id="P2" count="259"/>
                <participants group_id="P3" count="251"/>
                <participants group_id="P4" count="287"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="145"/>
                <participants group_id="P4" count="112"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Demographic data are available for participants who were included in the &quot;treated&quot; analysis population of 1,581 participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Flibanserin 25 mg b.i.d</title>
          <description>flibanserin: 25 mg twice daily</description>
        </group>
        <group group_id="B2">
          <title>Flibanserin 50mg Qhs/b.i.d</title>
          <description>flibanserin: 50 mg once at bedtime/twice daily</description>
        </group>
        <group group_id="B3">
          <title>Flibanserin 50mg b.i.d./100mg Qhs</title>
          <description>flibanserin: 50 mg twice daily/100 once at bedtime</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>flibanserin: placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="396"/>
            <count group_id="B2" value="392"/>
            <count group_id="B3" value="395"/>
            <count group_id="B4" value="398"/>
            <count group_id="B5" value="1581"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="396"/>
                    <measurement group_id="B2" value="392"/>
                    <measurement group_id="B3" value="395"/>
                    <measurement group_id="B4" value="398"/>
                    <measurement group_id="B5" value="1581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="396"/>
                    <measurement group_id="B2" value="392"/>
                    <measurement group_id="B3" value="395"/>
                    <measurement group_id="B4" value="398"/>
                    <measurement group_id="B5" value="1581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="341"/>
                    <measurement group_id="B2" value="345"/>
                    <measurement group_id="B3" value="334"/>
                    <measurement group_id="B4" value="343"/>
                    <measurement group_id="B5" value="1363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="346"/>
                    <measurement group_id="B2" value="344"/>
                    <measurement group_id="B3" value="349"/>
                    <measurement group_id="B4" value="352"/>
                    <measurement group_id="B5" value="1391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Frequency of Satisfying Sexual Events (SSE) as Recorded in the eDiary.</title>
        <description>For endpoints collected on the eDiary, responses are accumulated on a monthly basis using the following algorithms.
For satisfying sexual events:
Total monthly events = 28 x (sum of the number of events) / (sum of number of days entered)</description>
        <time_frame>baseline to 28 weeks</time_frame>
        <population>Participants who received at least one post-dose on-treatment efficacy assessment were included in the Full Analysis Set (FAS). Efficacy endpoints were analyzed primarily using the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Flibanserin 25 mg b.i.d</title>
            <description>flibanserin: 25 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Flibanserin 50mg Qhs/b.i.d</title>
            <description>flibanserin: 50 mg once at bedtime/twice daily</description>
          </group>
          <group group_id="O3">
            <title>Flibanserin 50mg b.i.d./100mg Qhs</title>
            <description>flibanserin: 50 mg twice daily/100 once at bedtime</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>flibanserin: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Frequency of Satisfying Sexual Events (SSE) as Recorded in the eDiary.</title>
          <description>For endpoints collected on the eDiary, responses are accumulated on a monthly basis using the following algorithms.
For satisfying sexual events:
Total monthly events = 28 x (sum of the number of events) / (sum of number of days entered)</description>
          <population>Participants who received at least one post-dose on-treatment efficacy assessment were included in the Full Analysis Set (FAS). Efficacy endpoints were analyzed primarily using the FAS.</population>
          <units>SSEs per 28 days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="369"/>
                <count group_id="O3" value="371"/>
                <count group_id="O4" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="3.5"/>
                    <measurement group_id="O2" value="1.4" spread="3.4"/>
                    <measurement group_id="O3" value="1.9" spread="5.3"/>
                    <measurement group_id="O4" value="1.1" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Monthly Sum of Responses Recorded in the eDiary to the Daily Desire Question.</title>
        <description>Change from baseline in the electronic diary (eDiary) Sexual Desire Monthly Total Score standardized to a 28-day period (score range 0-84). Change from baseline is calculated as the difference between the four week baseline period and Week 21 to Week 24. Patients were asked to record information daily in the eDiary throughout the trial. Every time the eDiary was completed, a desire question was asked. If a patient did not complete the diary on a given day, the patient was not asked to enter desire information for more than a 24-hour retrospective period. The desire item read &quot;Indicate your most intense level of sexual desire in the last 24 hours / since your last visit.‚Äù Potential responses included &quot;no,&quot; ‚Äúlow,‚Äù ‚Äúmoderate,‚Äù or ‚Äústrong‚Äù and was scored 0-3, with 0 indicating no desire and 3 indicating the highest level of desire:
0 = No desire
= Low desire
= Moderate desire
= Strong desire</description>
        <time_frame>baseline to 24 weeks</time_frame>
        <population>Participants who received at least one post-dose on-treatment efficacy assessment were included in the Full Analysis Set (FAS). Efficacy endpoints were analyzed primarily using the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Flibanserin 25 mg b.i.d</title>
            <description>flibanserin: 25 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Flibanserin 50mg Qhs/b.i.d</title>
            <description>flibanserin: 50 mg once at bedtime/twice daily</description>
          </group>
          <group group_id="O3">
            <title>Flibanserin 50mg b.i.d./100mg Qhs</title>
            <description>flibanserin: 50 mg twice daily/100 once at bedtime</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>flibanserin: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Monthly Sum of Responses Recorded in the eDiary to the Daily Desire Question.</title>
          <description>Change from baseline in the electronic diary (eDiary) Sexual Desire Monthly Total Score standardized to a 28-day period (score range 0-84). Change from baseline is calculated as the difference between the four week baseline period and Week 21 to Week 24. Patients were asked to record information daily in the eDiary throughout the trial. Every time the eDiary was completed, a desire question was asked. If a patient did not complete the diary on a given day, the patient was not asked to enter desire information for more than a 24-hour retrospective period. The desire item read &quot;Indicate your most intense level of sexual desire in the last 24 hours / since your last visit.‚Äù Potential responses included &quot;no,&quot; ‚Äúlow,‚Äù ‚Äúmoderate,‚Äù or ‚Äústrong‚Äù and was scored 0-3, with 0 indicating no desire and 3 indicating the highest level of desire:
0 = No desire
= Low desire
= Moderate desire
= Strong desire</description>
          <population>Participants who received at least one post-dose on-treatment efficacy assessment were included in the Full Analysis Set (FAS). Efficacy endpoints were analyzed primarily using the FAS.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="369"/>
                <count group_id="O3" value="371"/>
                <count group_id="O4" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="0.8"/>
                    <measurement group_id="O2" value="8.8" spread="0.8"/>
                    <measurement group_id="O3" value="8.5" spread="0.8"/>
                    <measurement group_id="O4" value="6.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Flibanserin 25 mg b.i.d</title>
          <description>flibanserin: 25 mg twice daily</description>
        </group>
        <group group_id="E2">
          <title>Flibanserin 50mg Qhs/b.i.d</title>
          <description>flibanserin: 50 mg once at bedtime/twice daily</description>
        </group>
        <group group_id="E3">
          <title>Flibanserin 50mg b.i.d./100mg Qhs</title>
          <description>flibanserin: 50 mg twice daily/100 once at bedtime</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>flibanserin: placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="392"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="395"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Cholecystitic acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="392"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrustion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="396"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="396"/>
                <counts group_id="E2" subjects_affected="293" subjects_at_risk="392"/>
                <counts group_id="E3" subjects_affected="266" subjects_at_risk="395"/>
                <counts group_id="E4" subjects_affected="133" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="396"/>
                <counts group_id="E2" events="51" subjects_affected="42" subjects_at_risk="392"/>
                <counts group_id="E3" events="54" subjects_affected="47" subjects_at_risk="395"/>
                <counts group_id="E4" events="18" subjects_affected="16" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="396"/>
                <counts group_id="E2" events="64" subjects_affected="60" subjects_at_risk="392"/>
                <counts group_id="E3" events="40" subjects_affected="38" subjects_at_risk="395"/>
                <counts group_id="E4" events="29" subjects_affected="27" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="396"/>
                <counts group_id="E2" events="65" subjects_affected="54" subjects_at_risk="392"/>
                <counts group_id="E3" events="54" subjects_affected="48" subjects_at_risk="395"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="32" subjects_affected="29" subjects_at_risk="396"/>
                <counts group_id="E2" events="73" subjects_affected="64" subjects_at_risk="392"/>
                <counts group_id="E3" events="55" subjects_affected="47" subjects_at_risk="395"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="37" subjects_affected="29" subjects_at_risk="396"/>
                <counts group_id="E2" events="65" subjects_affected="35" subjects_at_risk="392"/>
                <counts group_id="E3" events="68" subjects_affected="45" subjects_at_risk="395"/>
                <counts group_id="E4" events="53" subjects_affected="37" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="396"/>
                <counts group_id="E2" events="25" subjects_affected="20" subjects_at_risk="392"/>
                <counts group_id="E3" events="30" subjects_affected="25" subjects_at_risk="395"/>
                <counts group_id="E4" events="21" subjects_affected="20" subjects_at_risk="398"/>
              </event>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="396"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="392"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="395"/>
                <counts group_id="E4" events="13" subjects_affected="11" subjects_at_risk="398"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scientific Program Director</name_or_title>
      <organization>Sprout Pharmaceuticals</organization>
      <phone>9198820850</phone>
      <email>clinicaltrials@sproutpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

